Although the effects of SAM on reducing amyloid material has previously been reported28, 29, this is to our knowledge, the first report on SAM’s capacity to lower BACE-1 activity as well as increase neprilysin and IDE levels in a genetically triggered model of AD in vivo. The gene discussed is MME; the disease is Alzheimer disease.